➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Medtronic
Johnson and Johnson
Baxter
AstraZeneca

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RYDAPT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Rydapt

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03207334 iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia Not yet recruiting Novartis Pharmaceuticals Phase 2 2017-10-01 This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML.
NCT03207334 iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia Not yet recruiting University of Florida Phase 2 2017-10-01 This is an open label, single arm study of midostaurin in patients with relapsed or refractory AML.
NCT03836209 Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Not yet recruiting Astellas Pharma Inc Phase 2 2019-07-01 Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation. Gilteritinib, is an oral drug that works by stopping the leukemia cells from making the FLT3 protein. This may help stop the leukemia cells from growing faster and thus may help make chemotherapy more effective. Gilteritinib has been approved by the Food and Drug Administration (FDA) for patients who have relapsed or refractory AML with a FLT3 mutation but is not approved by the FDA for newly diagnosed FLT3 AML, and its use in this setting is considered investigational. Midostaurin is an oral drug that works by blocking several proteins on cancer cells, including FLT3 that can help leukemia cells grow. Blocking this pathway can cause death to the leukemic cells. Midostaurin is approved by the FDA for the treatment of FLT3 AML. The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rydapt

Condition Name

Condition Name for Rydapt
Intervention Trials
Acute Myeloid Leukemia 6
Myelodysplastic Syndrome With Excess Blasts-2 1
AML/MDS 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rydapt
Intervention Trials
Leukemia, Myeloid, Acute 6
Leukemia, Myeloid 6
Leukemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rydapt

Trials by Country

Trials by Country for Rydapt
Location Trials
Germany 2
United States 2
Netherlands 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rydapt
Location Trials
Oregon 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rydapt

Clinical Trial Phase

Clinical Trial Phase for Rydapt
Clinical Trial Phase Trials
Phase 3 1
Phase 2 3
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rydapt
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rydapt

Sponsor Name

Sponsor Name for Rydapt
Sponsor Trials
Stichting Hemato-Oncologie voor Volwassenen Nederland 2
Novartis Pharmaceuticals 2
Pfizer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rydapt
Sponsor Trials
Other 10
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
McKinsey
Medtronic
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.